caa a22 4500 606158650 CHVBK 20210128100620.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10557-015-6617-2 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6617-2 Effects of Ticagrelor on Ionic Currents and Contractility in Rat Ventricular Myocytes [Elektronische Daten] [Murathan Kucuk, Murat Celen, Bilge Yamasan, Yusuf Olgar, Semir Ozdemir] Purpose: Antiplatelet therapy has been widely used for management of patients with ischaemic heart diseases or thrombotic events. Experimental studies have shown that ticlopidine and clopidogrel decreased L-type Ca2+ currents (ICaL), altered action potential (AP) duration and thence exerted negative inotropic effects. In this study we tested if ticagrelor, a non-thienopyridine agent, has any influence on contractile and electrical properties of isolated ventricular myocytes. Methods: Cardiomyocytes were isolated from male rat hearts with an enzymatic dissociation procedure and left ventricular myocytes were used for experiments. The effects of ticagrelor (1μM) on sarcomere shortening, ionic currents and action potentials were measured at 36 ± 1°C. Results: Ticagrelor significantly reduced ICaL density (~18%, p < 0.01) of ventricular myocytes and this effect was reversible. In consistence, it also decreased sarcomere shortening of electrically stimulated cardiomyocytes (13%, p < 0.05), while it did not change relaxation rates. Repolarizing K+ currents and AP duration were unaffected by 1μM ticagrelor application. Conclusions: Ticagrelor exerts a significant influence on contractile properties and membrane currents of ventricular myocytes similarly to thienopyridine agents. The impact of ticagrelor on cardiac excitation-contraction coupling elements is important, since it is widely used for the treatment of patients with heart diseases. Springer Science+Business Media New York, 2015 Ticagrelor nationallicence Ventricular myocytes nationallicence L-type Ca2+ currents nationallicence Contractility nationallicence Action potential nationallicence Kucuk Murathan Faculty of Medicine Department of Cardiology, Akdeniz University, Antalya, Turkey aut Celen Murat Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut Yamasan Bilge Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut Olgar Yusuf Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut Ozdemir Semir Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/5(2015-10-01), 419-424 0920-3206 29:5<419 2015 29 10557 https://doi.org/10.1007/s10557-015-6617-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6617-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kucuk Murathan Faculty of Medicine Department of Cardiology, Akdeniz University, Antalya, Turkey aut NATIONALLICENCE 700 1- Celen Murat Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut NATIONALLICENCE 700 1- Yamasan Bilge Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut NATIONALLICENCE 700 1- Olgar Yusuf Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut NATIONALLICENCE 700 1- Ozdemir Semir Faculty of Medicine Department of Biophysics, Akdeniz University, Antalya, Turkey aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/5(2015-10-01), 419-424 0920-3206 29:5<419 2015 29 10557